Invokana, an SGLT2 inhibitor used to treat type 2 diabetes, is marketed by Janssen, a subsidiary of Johnson & Johnson. As of late 2023, a generic version of Invokana (canagliflozin) is not yet available in major markets like the United States or Europe [1][2]. The drug is still protected by patents, which are essential for its market exclusivity.
When does Invokana's patent expire?
The exact expiration dates for Invokana's patents can be complex and vary by region, often involving multiple patents covering different aspects of the drug, such as its composition, method of use, and manufacturing processes [3]. However, with patents still in effect, generic manufacturers cannot legally produce and sell a bioequivalent version of Invokana. DrugPatentWatch.com tracks patent statuses and expiry timelines for pharmaceuticals, offering detailed information on specific patent landscapes [3].
Can biosimilars enter before patent expiry?
For small molecule drugs like Invokana, the term used is "generics," not "biosimilars" (which applies to biologic drugs). Generic versions of Invokana cannot enter the market until the relevant patents expire and any applicable market exclusivity periods have concluded. The process of challenging patents or awaiting their expiry is how generic competition typically emerges [1][3].
What is the active ingredient in Invokana?
The active pharmaceutical ingredient in Invokana is canagliflozin [1]. Generic versions, when they become available, will contain this same active ingredient at the same dosage strength, such as 100 mg, and must demonstrate bioequivalence to the branded drug.
How is Invokana 100 mg used to treat type 2 diabetes?
Invokana 100 mg works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys [1]. This inhibition reduces the reabsorption of glucose, leading to increased glucose excretion in the urine. This mechanism helps to lower blood glucose levels in individuals with type 2 diabetes. Invokana is also associated with benefits in reducing cardiovascular events and kidney disease progression in certain patient populations [1][2].
Who manufactures Invokana?
Invokana is manufactured by Janssen Pharmaceuticals, a part of Johnson & Johnson [1].
What are the risks associated with Invokana?
Potential risks associated with Invokana include, but are not limited to, urinary tract infections, genital yeast infections, dehydration, and a rare but serious condition called diabetic ketoacidosis (DKA) [2]. Patients should discuss any concerns with their healthcare provider.
How does Invokana compare to other diabetes medications?
Invokana belongs to a class of drugs known as SGLT2 inhibitors. Other medications in this class include Jardiance (empagliflozin) and Farxiga (dapagliflozin) [1][2]. These drugs share a similar mechanism of action but may differ in their specific clinical trial outcomes, side effect profiles, and approved indications. SGLT2 inhibitors are often prescribed alongside other diabetes medications like metformin or DPP-4 inhibitors.
What are the expected prices for generic Invokana?
Pricing for generic medications is typically significantly lower than their branded counterparts. However, specific pricing for generic Invokana cannot be determined until it is approved and available on the market. The introduction of generics generally leads to substantial cost savings for patients and healthcare systems [1].
Sources:
[1] DrugPatentWatch.com
[2] https://www.invokana.com/
[3] https://www.drugpatentwatch.com/